DrugPatentWatch, a provider of global biopharmaceutical business intelligence, has entered into a partnership with Adis. The partner will enhance Adis’ […]
DrugPatentWatch Partners with Adis: Helping Drug Companies Make Better Decisions Read Post »
Branded generics are generic drugs that have been given proprietary brand names. They have a small, but profitable place in the U.S. pharmaceutical market.
Branded Generics and Why They’re Profitable Read Post »
Pharmaceutical life cycle management begins earlier and ends later to maximize stakeholder value in all phases of drug development.
For readers following the the Biologic Patent Transparency Act, DrugPatentWatch has recently been cited in an article describing the act as
DrugPatentWatch in the news: The Biologic Patent Transparency Act. Read Post »
1. What This Article Covers and Why It Matters Now The baseline 20-year patent term for a small molecule drug
Healthcare systems including hospitals are taking care-related and business-related steps to cope with rapidly increasing drug prices.
The High-Stakes Game: How Healthcare Systems Are Coping with Soaring Drug Prices Read Post »
Information contained in expired drug patents can be invaluable to researchers developing new products, but caution is required to avoid legal problems.
A comprehensive analysis for pharma IP teams, portfolio managers, payer strategy leads, and institutional investors examining the structural economics, IP
The global generic drugs market was valued at $468.08 billion in 2025 and is projected to reach $728.64 billion by
Get fresh news and insights, drug patent expirations & more…
